The Economic Club of Canada: The Life Sciences Industry of Tomorrow: Healthy Canadians, Healthy Future
OTTAWA, Oct. 30, 2017 /CNW/ – What is the true contribution of the innovative pharmaceutical industry to the Canadian economy and R&D investment? What are the potential impacts of federal policy changes aimed at lowering drug prices? Is there a middle ground where Canada is able to lower prices while still retaining its position as a top tier destination for clinical trials and the launch of new innovative medicines? Innovative Medicines Canada President Pamela Fralick and panelists will discuss the results of a Fall 2017 analysis by Ernst & Young about industry’s contributions to Canada and how industry and government can work together to enhance affordable, equitable and timely access to new therapies.
The event will be broadcast live over the internet at http://collaboratevideo.net/imc-mnc
Innovative Medicines Canada President Pamela Fralick will be available for media interviews after the event.
Pamela C. Fralick: President – Innovative Medicines Canada
Connie Côté, Chief Executive Officer, Health Charities Coalition of Canada
Dr. Bill Cameron, Senior Scientist, Division of Infectious Diseases and Respirology, Medical Director, Clinical Research, Ottawa Hospital Research Institute
Ed Dybka, President and CEO – AstraZeneca Canada Inc.
|WHEN:||Tuesday, October 31, 2017 (11:30am-1:30pm)|
|11:15 am||Registration begins|
|12:15 pm||Opening remarks begin|
|12:25 pm||Keynote speech begin|
|1:30 pm||Event concludes|
|WHERE:||Fairmont Chateau Laurier
1 Rideau Street, Ottawa
About Innovative Medicines Canada
Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.